4506.T
Sumitomo Pharma Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 1,673.50
+2.45%Year over year
Reported trailing growth
- Revenue
- +13.7%
- EBITDA
- —
- EBIT
- +272.6%
- EPS
- +352.2%
- Free cash flow
- +738.6%
- Operating cash flow
- +334.6%
Forward estimates
Based on analyst estimates
- Revenue
- -5.4%
- EBITDA
- —
- EPS
- -13.9%
Three-year CAGR
- Revenue
- -6.6%
- EBITDA
- +135.7%
- EBIT
- +272.6%
- Net income
- +352.2%
- EPS
- +352.2%
- Free cash flow
- +168.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026